ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0780

Subsets of Synovial Fluid Derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis

Kuninobu Wakabayashi1, Takeo Isozaki1, Shin Ohta2 and Tsuyoshi Kasama3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan

Meeting: ACR Convergence 2020

Keywords: Fibroblasts, Synovial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) secrete inflammatory cytokines and chemokines, invade and degrade cartilage, and stimulate osteoclast that cause bone erosion. Recently, it is reported that the subsets of RA FLS in fresh human synovial tissues were characterized by the expression of podoplanin (PDPN), CD34, and THY1 (also known as CD90). Especially PDPN+CD34–THY1+ FLS may be pathogenic since these cells secrete proinflammatory cytokines and are proliferative and invasive. Adherent cells with FLS appearance are observed when the cells in synovial fluid (SF) are cultured. The aim of this study is to investigate the subsets of SF-derived FLS in RA.

Methods: We collected the SFs aspirated from the knee joint of RA patients, who were not treated with DMARDs at the onset or at the flare. The SFs were centrifuged and the cell pellets were resuspended in RPMI-1640 medium supplemented with 10% FBS and 1% Pen-Strep. The attached cells were cultured until 80% confluent growth was observed, and these cells were harvested and passaged. The profile of cell surface markers expressed by SF-derived adherent cells were analyzed using flow cytometry. Flow cytometry was performed by triple staining with PDPN, CD34 and THY1. The data are reported as the mean ± SE.

Results: We got the synovial fluid from 17 patients with RA. The characteristics of the 8 patients, whose SF-derived adherent cells were able to be passaged, were long duration of arthralgia (102.1 ± 35.1 vs 11.0 ± 6.9 months, p< 0.05), lower levels of serum rheumatoid factor (30.9 ± 15.5 vs 152.0 ± 48.9 IU/mL, p< 0.05) and lower proportion of lymphocytes of white blood cells in SF ( 11.4 ± 3.2 vs 39.0 ± 10.6 %, p< 0.05). At the passage 0 (n=8), PDPN+ cells were lower than PDPN– cells (35.6 ± 4.1 % and 64.4 ± 4.1 %, respectively, p< 0.05). The proportion of CD34–THY1+, CD34–THY1–, CD34+THY1+, and CD34+THY1– in the PDPN+ cells were 54.2 ± 10.8 %, 25.7 ± 12.2 %, 23.1 ± 9.2 %, and 2.2 ± 0.3 % respectively. Among the 3 patients whose cells were passaged up to P2, the rate of PDPN+ cells were increased with every repeated the passage (P0: 28.8 ± 4.4 %, P1: 60.3 ± 7.7 %, P2: 71.4 ± 3.2 %). In addition, the rate of CD34+THY1+ cells in the PDPN+ cells were increased (P0: 4.4 ± 1.7 %, P1: 16.9 ± 6.8 %, P2: 25.4 ± 6.0 %).

Conclusion:

These data show that PDPN+ SF-derived FLS have the subsets, and CD34–THY1+ cells would be major subsets. PDPN+ SF-derived FLS, particularly CD34+THY1+ cells, are proliferative. Considering SF-derived FLS have the merit of easy accessibility, these cells could substitute for ST-derived FLS in studying the pathogenesis of RA.


Disclosure: K. Wakabayashi, None; T. Isozaki, None; S. Ohta, None; T. Kasama, None.

To cite this abstract in AMA style:

Wakabayashi K, Isozaki T, Ohta S, Kasama T. Subsets of Synovial Fluid Derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/subsets-of-synovial-fluid-derived-fibroblast-like-synoviocytes-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subsets-of-synovial-fluid-derived-fibroblast-like-synoviocytes-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology